Oral Semaglutide Cuts Daily Food Intake by 39% and Improves Eating Control
Oral semaglutide reduced ad libitum daily energy intake by 39% versus placebo in type 2 diabetes patients, with increased satiety after fatty meals, fewer cravings, and 2.7 kg weight loss from body fat.
Quick Facts
What This Study Found
Oral semaglutide 14mg reduced total daily ad libitum energy intake by 38.9% versus placebo (treatment difference -5,096 kJ, p=0.0001). Increased satiety and fullness after fat-rich breakfast. Body weight decreased 2.7 kg (mostly fat mass) vs 0.1 kg placebo.
Key Numbers
38.9% energy intake reduction; 5,096 kJ/day difference; 2.7 kg weight loss vs 0.1 kg; P=0.0001
How They Did This
Randomized, double-blind, placebo-controlled, two-period crossover trial. 15 subjects with T2D. 12 weeks oral semaglutide (escalated 3→7→14 mg) vs placebo. Ad libitum energy intake, appetite VAS ratings after standard and fat-rich breakfasts, Control of Eating Questionnaire, body composition.
Why This Research Matters
Understanding exactly how GLP-1 drugs reduce food intake helps explain their weight loss effects and informs clinical use. The 39% calorie reduction explains the meaningful weight loss seen in larger trials.
The Bigger Picture
This mechanistic study demonstrates that oral semaglutide's weight loss is driven by genuine appetite suppression — reduced hunger, increased satiety, fewer cravings — rather than just gastrointestinal side effects. This supports the biological rationale for GLP-1 drugs as obesity treatments.
What This Study Doesn't Tell Us
Very small study (15 subjects, 13 evaluable). Short duration (12 weeks). Crossover design in T2D patients — results may differ in non-diabetic obesity. Laboratory meal setting may not reflect real-world eating behavior.
Questions This Raises
- ?Does the 39% calorie reduction persist with longer-term use or does tolerance develop?
- ?Which specific foods or macronutrients are most reduced by semaglutide?
- ?Would the appetite effects be similar in people without diabetes?
Trust & Context
- Key Stat:
- 39% less food intake Oral semaglutide 14mg reduced voluntary daily calorie consumption by 39% versus placebo, demonstrating genuine appetite suppression as the mechanism for weight loss
- Evidence Grade:
- Moderate evidence: randomized, double-blind, placebo-controlled crossover design, but very small sample (15 subjects).
- Study Age:
- Published 2021. Oral semaglutide (Rybelsus) is now widely prescribed, and its appetite effects are well-established in clinical practice.
- Original Title:
- Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.
- Published In:
- Diabetes, obesity & metabolism, 23(2), 581-588 (2021)
- Authors:
- Gibbons, Catherine, Blundell, John, Tetens Hoff, Søren, Dahl, Kirsten, Bauer, Robert, Baekdal, Tine
- Database ID:
- RPEP-05404
Evidence Hierarchy
Frequently Asked Questions
Does semaglutide actually make you eat less?
Yes. This controlled study showed oral semaglutide reduced voluntary food intake by 39% compared to placebo. Patients felt fuller, had fewer cravings, and reported better control over their eating — not just nausea-related appetite loss.
Does the weight loss from semaglutide come from fat?
In this study, the 2.7 kg weight loss was mostly from body fat mass, which is the ideal composition of weight loss. This suggests semaglutide preferentially reduces fat rather than muscle.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05404APA
Gibbons, Catherine; Blundell, John; Tetens Hoff, Søren; Dahl, Kirsten; Bauer, Robert; Baekdal, Tine. (2021). Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.. Diabetes, obesity & metabolism, 23(2), 581-588. https://doi.org/10.1111/dom.14255
MLA
Gibbons, Catherine, et al. "Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.." Diabetes, 2021. https://doi.org/10.1111/dom.14255
RethinkPeptides
RethinkPeptides Research Database. "Effects of oral semaglutide on energy intake, food preferenc..." RPEP-05404. Retrieved from https://rethinkpeptides.com/research/gibbons-2021-effects-of-oral-semaglutide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.